{"id":"https://openalex.org/W2051166675","doi":"https://doi.org/10.2174/1568007023339544","title":"Direct and Indirect Modulation of the N-Methyl D-Aspartate Receptor: Potential for the Development of Novel Antipsychotic Therapies","display_name":"Direct and Indirect Modulation of the N-Methyl D-Aspartate Receptor: Potential for the Development of Novel Antipsychotic Therapies","alternate_titles":[],"publication_year":2002,"publication_date":"2002-02-01","ids":{"openalex":"https://openalex.org/W2051166675","doi":"https://doi.org/10.2174/1568007023339544","mag":"2051166675","pmid":"https://pubmed.ncbi.nlm.nih.gov/12769631"},"language":"en","primary_location":{"id":"doi:10.2174/1568007023339544","doi":"https://doi.org/10.2174/1568007023339544","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568007023339544","pdf_url":null,"source":{"id":"https://openalex.org/S148418319","display_name":"CNS & Neurological Disorders - Drug Targets","issn_l":"1568-007X","issn":["1568-007X","1871-5273","1996-3181","2212-5299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Target -CNS &amp; Neurological Disorders","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2051166675"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085972667","display_name":"Michael J. Marino","orcid":"https://orcid.org/0000-0002-8672-0310","observed_orcids":["https://orcid.org/0000-0002-8672-0310","https://orcid.org/0009-0008-9118-0225"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Marino","raw_affiliation_strings":["Emory University, Department of Pharmacology, Atlanta, GA 30322, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University, Department of Pharmacology, Atlanta, GA 30322, USA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026609125","display_name":"Peter Jeffrey Conn","orcid":"https://orcid.org/0000-0003-2363-0323","observed_orcids":["https://orcid.org/0000-0003-2363-0323"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Conn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.9934,"has_fulltext":false,"cited_by_count":145,"citation_normalized_percentile":{"value":0.93361933,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"1","issue":"1","first_page":"1","last_page":"16"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.043699998408555984,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12770","display_name":"Amino Acid Enzymes and Metabolism","score":0.009499999694526196,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nmda-receptor","display_name":"NMDA receptor","score":0.9169999957084656},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9490000009536743},{"id":"https://openalex.org/keywords/antipsychotic-drug-development","display_name":"antipsychotic drug development","score":0.8479999899864197},{"id":"https://openalex.org/keywords/glutamatergic-system","display_name":"glutamatergic system","score":0.847000002861023},{"id":"https://openalex.org/keywords/dopamine-hypothesis","display_name":"dopamine hypothesis","score":0.5429999828338623},{"id":"https://openalex.org/keywords/dopamine-d2-receptor","display_name":"dopamine D2 receptor","score":0.8840000033378601},{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.9649999737739563},{"id":"https://openalex.org/keywords/muscarinic-receptors","display_name":"muscarinic receptors","score":0.8989999890327454},{"id":"https://openalex.org/keywords/metabotropic-glutamate-receptors","display_name":"metabotropic glutamate receptors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/g-protein-coupled-receptors","display_name":"G protein-coupled receptors","score":0.8100000023841858},{"id":"https://openalex.org/keywords/receptor-modulation","display_name":"receptor modulation","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.8161942958831787},{"id":"https://openalex.org/C2781065190","wikidata":"https://www.wikidata.org/wiki/Q7256512","display_name":"Psychotomimetic","level":4,"score":0.7925001382827759},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.735106348991394},{"id":"https://openalex.org/C25876315","wikidata":"https://www.wikidata.org/wiki/Q15197465","display_name":"Neurochemical","level":2,"score":0.6870196461677551},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.6641813516616821},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6026888489723206},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.49971699714660645},{"id":"https://openalex.org/C170457331","wikidata":"https://www.wikidata.org/wiki/Q1242622","display_name":"Dopamine hypothesis of schizophrenia","level":4,"score":0.4996166229248047},{"id":"https://openalex.org/C26702167","wikidata":"https://www.wikidata.org/wiki/Q901988","display_name":"Metabotropic receptor","level":4,"score":0.46326735615730286},{"id":"https://openalex.org/C49051014","wikidata":"https://www.wikidata.org/wiki/Q2033959","display_name":"Metabotropic glutamate receptor","level":4,"score":0.4217067360877991},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4134332239627838},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35891902446746826},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.3583593964576721},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3556835651397705},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33374133706092834},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.32775846123695374},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.2717489004135132},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.21343371272087097},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12703275680541992}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013678","descriptor_name":"Technology, Pharmaceutical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D017470","descriptor_name":"Receptors, Glutamate","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/1568007023339544","doi":"https://doi.org/10.2174/1568007023339544","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1568007023339544","pdf_url":null,"source":{"id":"https://openalex.org/S148418319","display_name":"CNS & Neurological Disorders - Drug Targets","issn_l":"1568-007X","issn":["1568-007X","1871-5273","1996-3181","2212-5299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Target -CNS &amp; Neurological Disorders","raw_type":"journal-article"},{"id":"pmid:12769631","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12769631","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current drug targets. CNS and neurological disorders","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2097693079","https://openalex.org/W4402317514","https://openalex.org/W2166241992","https://openalex.org/W2008639041","https://openalex.org/W1507804974","https://openalex.org/W2108610913","https://openalex.org/W1985064537","https://openalex.org/W1490991280","https://openalex.org/W1980393143","https://openalex.org/W2093248761"],"abstract_inverted_index":{"The":[0],"dopamine":[1,53],"hypothesis":[2,124],"of":[3,14,16,36,42,85,91,125,173,181],"schizophrenia":[4,86],"has":[5,28,55],"been":[6,29,65],"a":[7,33,40,69,134],"driving":[8],"force":[9],"in":[10,22,31,60,72,104],"guiding":[11],"both":[12],"theories":[13],"pathophysiology":[15],"schizophrenia,":[17,126],"and":[18,39,87,127,158],"drug":[19],"discovery":[20],"efforts":[21],"this":[23,26,117],"area.":[24],"While":[25],"path":[27],"fruitful":[30],"producing":[32],"deeper":[34],"understanding":[35],"the":[37,51,61,73,80,83,88,105,121,130,145,156,164,171,179],"disorder":[38],"variety":[41],"antipsychotic":[43,139],"drugs,":[44],"it":[45],"is":[46],"generally":[47],"recognized":[48],"that":[49,107,162,176],"targeting":[50],"D(2)":[52],"receptor":[54,96,110,132],"multiple":[56],"shortcomings.":[57],"Recently,":[58],"alterations":[59],"glutamatergic":[62],"system":[63],"have":[64,101],"proposed":[66],"to":[67],"play":[68],"key":[70],"role":[71],"neurochemical":[74],"disruptions":[75],"underlying":[76],"schizophrenia.":[77,115,182],"In":[78,116],"particular,":[79],"similarities":[81],"between":[82],"symptoms":[84,180],"psychotomimetic":[89],"effects":[90],"non-competitive":[92],"N-methyl":[93],"D-aspartate":[94],"(NMDA)":[95],"antagonists":[97],"such":[98,154],"as":[99,133,148,150,155],"phencyclidine":[100],"spurred":[102],"interest":[103],"possibility":[106],"an":[108],"NMDA":[109,122,131,146,165],"hypofunctional":[111],"state":[112],"might":[113],"underlie":[114],"review,":[118],"we":[119],"summarize":[120],"hypofunction":[123],"focus":[128],"on":[129,144],"potential":[135,168],"target":[136],"for":[137,170],"novel":[138,174],"agents.":[140],"Both":[141],"modulatory":[142],"sites":[143],"receptor,":[147,166],"well":[149],"G-protein":[151],"coupled":[152],"receptors":[153,161],"muscarinic":[157],"metabotropic":[159],"glutamate":[160],"modulate":[163],"are":[167],"targets":[169],"development":[172],"compounds":[175],"could":[177],"ameliorate":[178]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2051166675","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
